Scandion Oncology
Overcoming cancer drug resistance

Navbar

About us
Research & Development
News & Press
- Press releases
- Media
  - Image library
  - Video library
Investors
Contact
- Career

Skip to content

INVESTOR

Analyst Coverage

Redeye

Christian Binder
christian.binder@redeye.se

Redeye’s corporate page on Scandion Oncology can be found here

Frontpage
Investors
Analyst Coverage

About us

About us
Executive Management
Board of Directors
Clinical Advisory Board

Research & Development

Research & Development
Pipeline
Clinical Development
Science

News & Press

Press releases
Other news
Media
- Image library items
- Video library items

Investors

Investors
Share information
Financial Reports
Presentations
Analyst Coverage
Prospectuses
Corporate governance
Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.